GALAPAGOS NV (GXE.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:GXE • BE0003818359
GXE.DE Key Statistics, Chart & Performance
The current stock price of GXE.DE is 28.12 EUR. In the past month the price decreased by -1.33%.
GXE.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GXE.DE.
GXE.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GXE.DE. While GXE.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
GXE.DE Financial Highlights
Over the last trailing twelve months GXE.DE reported a non-GAAP Earnings per Share(EPS) of -6.62. The EPS decreased by -311.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.42% | ||
| ROE | -17.83% | ||
| Debt/Equity | 0 |
GXE.DE Forecast & Estimates
19 analysts have analysed GXE.DE and the average price target is 31.09 EUR. This implies a price increase of 10.57% is expected in the next year compared to the current price of 28.12.
For the next year, analysts expect an EPS growth of -541.12% and a revenue growth -5.4% for GXE.DE
GXE.DE Ownership
GXE.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.4 | 43.108B | ||
| ARGX | ARGENX SE | 27.36 | 43.046B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.737B | ||
| 2X1 | ABIVAX SA | N/A | 7.625B | ||
| ABVX | ABIVAX SA | N/A | 7.601B | ||
| GLPG | GALAPAGOS NV | N/A | 1.857B | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| IVA | INVENTIVA SA | N/A | 963.467M | ||
| NANO | NANOBIOTIX | N/A | 868.079M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GXE.DE
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GXE.DE FAQ
What does GALAPAGOS NV do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 704 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
What is the stock price of GALAPAGOS NV today?
The current stock price of GXE.DE is 28.12 EUR. The price decreased by -1.68% in the last trading session.
What is the dividend status of GALAPAGOS NV?
GXE.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of GXE stock?
GXE.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for GALAPAGOS NV?
GALAPAGOS NV (GXE.DE) operates in the Health Care sector and the Biotechnology industry.
Is GALAPAGOS NV (GXE.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GXE.DE.
When does GALAPAGOS NV (GXE.DE) report earnings?
GALAPAGOS NV (GXE.DE) will report earnings on 2026-02-24, after the market close.